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Abstract
Background: The alveolar macrophage (AM) - first line of innate immune defence against pathogens and
environmental irritants - constitutively expresses peroxisome-proliferator activated receptor g (PPARg). PPARg ligand-
induced activation keeps the AM quiescent, and thereby contributes to combat invaders and resolve inflammation
by augmenting the phagocytosis of apoptotic neutrophils and inhibiting an excessive expression of inflammatory
genes. Because of these presumed anti-inflammatory functions of PPARg we tested the hypothesis, whether
reduced functional receptor availability in mutant mice resulted in increased cellular and molecular inflammatory
response during acute inflammation and/or in an impairment of its resolution.
Methods: To address this hypothesis we examined the effects of a carbon-nanoparticle (CNP) lung challenge, as
surrogate for non-infectious environmental irritants, in a murine model carrying a dominant-negative point
mutation in the ligand-binding domain of PPARg (P465L/wt). Animals were instilled intratracheally with Printex 90
CNPs and bronchoalveolar lavage (BAL) was gained 24 h or 72 h after instillation to investigate its cellular and
protein composition.
Results: Higher BAL cell numbers - due to higher macrophage counts - were found in mutants irrespective of
treatment. Neutrophil numbers in contrast were slightly lower in mutants. Intratracheal CNP instillation resulted in a
profound recruitment of inflammatory neutrophils into the alveolus, but genotype related differences at acute
inflammation (24 h) and resolution (72 h) were not observed. There were no signs for increased alveolar-capillary
membrane damage or necrotic cell death in mutants as determined by BAL protein and lactate-dehydrogenase
content. Pro-inflammatory macrophage-derived cytokine osteopontin was higher, but galectin-3 lower in female
mutants. CXCL5 and lipocalin-2 markers, attributed to epithelial cell stimulation did not differ.
Conclusions: Despite general genotype-related differences, we had to reject our hypothesis of an increased CNP
induced lung inflammation and an impairment of its resolution in PPARg defective mice. Although earlier studies
showed ligand-induced activation of nuclear receptor PPARg to promote resolution of lung inflammation, its
reduced activity did not provide signs of resolution impairment in the settings investigated here.
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Background
The peroxisome proliferator-activated receptor g (PPARg)
is expressed in several organs and tissues [1-3] and is
involved in the regulation of adipocyte differentiation and
glucose homeostasis [4-7], being a regulator of energy
homeostasis. PPARg has been involved in lung maturation
in mice [3,8] and its expression was found in immune
cells, like lymphocytes, macrophages, and granulocytes,
the latter mainly involved in inflammatory reactions
[9,10]. PPARg acts as a ligand-activated transcription
factor [11]. Prostaglandins [8,12], but also synthetic and
nonsteroidal anti-inflammatory substances [8,13] activate
the receptor. PPARg activation has been shown to exhibit
anti-inflammatory potential by inhibiting the activity of
pro-inflammatory transcription factors such as e.g. the
activator protein 1 (AP-1), signal transducer and activators
of transcription (STATs), or the Nuclear factor kappa B
(NF-B), as shown in murine primary peritoneal macro-
phages [14-16].
In particular alveolar macrophages (AM) have increased
levels of PPARg [9] and are constantly bathed in lipid-rich
surfactant [17] that consists of potential receptor activat-
ing ligands, or at least precursors of ligands [14,18,19].
This coexistence of high levels of PPARg in an environ-
ment rich in lipophilic ligands is an important finding,
since: i) resident AMs in the alveolus represent the first
line of innate immune defence in the respiratory tract and
ii) AM orchestrate inflammatory responses by recognizing
tissue damage, promoting neutrophil recruitment for
appropriate pathogen defence and finally leading to resolu-
tion of inflammation [20]. This indispensable role in lung
homeostasis makes the AM a promising target for the
treatment of inflammatory lung diseases. In fact murine
studies have revealed AM function requires upregulation
of the expression of CD36, a PPARg target. CD36 is a cell
surface scavenger receptor and a key factor promoting
phagocytosis of apoptotic neutrophils, lipids and unopso-
nized materials [18]. Similarly, an increase in Fcg receptor
mediated phagocytosis of opsonized materials [21] seems
to require PPARg activation. This AM cell-mediated effec-
tor promoting resolution of inflammation depends on the
PPARg-induced molecular anti-inflammatory properties
[22] as well as by factors of different lung structural cell
types, thereby down-regulating pro-inflammatory media-
tors [10] like TNFa, neutrophil and monocyte-macro-
phage chemotactic factors IL-8, MCP-1, pro-oxidant
enzyme iNOS, and MMP9 [23-25] while up-regulating
expression of anti-inflammatory proteins like IL-10
(reviewed in [9]). These results suggest a potential thera-
peutic application of PPARg activation to resolve lung
inflammatory disorders. This is particularly relevant since
AM play a critical role in pathogenesis of asthma, chronic
obstructive pulmonary disease (COPD), lung fibrosis (IPF)
and lung sarcoidosis (for review see [9]). Moreover PPARg
binding to the respective response elements in AMs is
markedly reduced in chronic inflammatory pulmonary sar-
coidosis and obstructive diseases [26,27]. This suggests
that the alveolar microenvironment might be immuno-
suppressive in the absence of a specific stimulus [28],
keeping the AM in a quiescent mode possibly supported
by PPARg function.
PPARg knockout models have already revealed develop-
mental airspace enlargement, and greater smoke-induced
emphysema, with increased AM numbers [3,8]. In agree-
ment with this beneficial effects of ligand-induced PPARg
activation in the lung [8,29] have been suggested, as indi-
cated by the attenuation of pro-inflammatory cytokine
release from activated AMs, eosinophils and type2 epithe-
lial cells [29], and reduced smoke-induced epithelial
mucin production [30]. Improved pathophysiological
states in models for asthma, COPD, IPF, and acute lung
injury have also been found [29,31-33]. In contrast, PPARg
deficiency or lack of receptor activation in macrophages
resulted in increased atherosclerosis [34] and reduced
CD36 expression [18,35]. Take together all together, these
findings highlight PPARg as a promising target for the
treatment of many inflammatory pathologies by promot-
ing resolution of inflammation [18].
According to these anti-inflammatory effects in the
lung and the fact that unresolved pulmonary inflamma-
tion may lead to chronic disease states, we tested the
hypothesis that a diminished PPARg function may result
in an increased cellular and molecular inflammatory
response, during acute inflammation and impaired reso-
lution. With regard to an inflammatory stimulation of
the lungs by particulate matter, so far PPARg function
has only been associated with exposure to cigarette
smoke but not with environmental particles such as com-
bustion derived nanoparticles. To address this hypothesis
we investigated mice (C57BL/6J) carrying a dominant-
negative point mutation (P465L) in the ligand-binding
domain of the PPARg receptor - a targeted mutation,
equivalent to a rare mutation in humans (P467L)
[5,36-38]. Whereas human carriers of the mutation suffer
from lipodystrophy, extreme insulin resistance, as well as
hypertension, fatty liver, and lower adiponectin levels in
circulation, humans with the homozygous for P465L die
in utero. Mice with the same mutation developed appar-
ently morphologically normal total amounts of adipose
tissue - although displaying higher extra-abdominal fat
mass - and were insulin sensitive [6,7]. However, these
animals recapitulated the human phenotype once chal-
lenged with positive energy balance [7]. We favoured to
use P465L/wt mutant mice over the more severely com-
promised PPARg knock-out mice since it more reliably
resembles the situation in chronic inflammatory lung
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diseases as described, in alveolar macrophages - like in
asthma [39], pulmonary sarcoidosis [26,27] and COPD
[9] - or in epithelial cells like in cystic fibrosis [40], where
PPARg activation was found to be reduced, but not
absent. Our rational was that if PPARg contributes to an
anti-inflammatory macrophage state and/or is involved
in the resolution of inflammation, then PPARg defective
mice should show impaired resolution of particle induced
lung inflammation, a model clearly involving alveolar
macrophage function [41,42].
To our knowledge, apart from cigarette smoke, yet no
one has investigated PPARg related effects in the context
of particle related lung inflammation. Exposure to Printex
90 was primarily chosen as a surrogate for urban air pollu-
tion by combustion derived nanoparticles. However since
in addition to its generation by combustion processes like
from diesel engines, carbon black is a constituent of lots
of products of modern societies, like inks and paints, rub-
ber and plastic, and thus progressively becoming a more
relevant anthropogenic source of ambient and indoor par-
ticulate matter. In fact more than 10 million tones are pro-
duced every year [43]. But regardless of CNP ancestry,
whether airborne, combustion derived or engineered, this
sub-100 nm scaled particle class has gained toxicological
interest due to their small dimensions, large surface area
and high deposition efficiency in the lung being considered
an important driver of adverse health effects linked to
respiratory toxicity [44,45]. It is widely accepted that parti-
culate air pollution contributes to the adverse health
effects in humans and that patients with metabolic syn-
drome (obesity, hypertension and diabetes mellitus) may
be a more susceptible population. Thus the identification
of underlying pathways linking the inflammatory
responses induced by particle related health effects and
susceptibility to metabolic diseases are of prime impor-
tance. In this respect we speculate that PPARg might be
one of the connections linking the regulation of lipid
metabolism with alveolar inflammation.
In summary our aim was on to contribute to the under-
standing of the pathogenic role of PPARg biology during
pulmonary inflammation caused by non-infectious respir-
able stimuli as represented by carbonaceous particulate
matter. We wanted to clarify whether the reduced avail-
ability of functional PPARg in (P465L/wt) mutant mice
increased the susceptibility towards acute inflammation
and failed resolution in response to CNP-stimulus in com-
parison to PPARg wild-type mice (wt/wt). Experiments
were performed in adult, 12-14 weeks old, PPARg wild-
type (wt/wt) and P465L/wt mutant mice of both genders
to account for sex-specific hormone levels [46,47].
Animals were challenged using physically and chemically
well characterized CNPs of moderate toxicity as described
earlier [41].
Results
Bronchoalveolar Lavage (BAL) cell analysis
Bronchoalveolar lavage (BAL) volumes obtained from
age- and body mass-matched PPARg wild-type (wt/wt)
and PPARg mutant mice (P465L/wt) did not reveal sig-
nificant differences between groups allowing an adequate
comparison of BAL cell differentials between groups.
Cytospin analysis showed significant differences in total
BAL cell numbers between genotypes. This was observed
in both sexes, being generally slightly higher in the
mutant group irrespectively of the treatment (Figure 1A
and 1E). This effect was due to higher macrophage
counts associated with the mutant genotype (Figure 1B
and 1F). In contrast the BAL neutrophil pool was lightly
lower in mutants (Figure 1C and 1G). Lymphocyte num-
bers did not differ between genotypes in both sexes
(Figure 1D and 1H). Significant interaction terms (treat-
ment × sex) indicated some sex-specific differences.
Compared to males, females displayed lower total BAL
cell numbers under control conditions but higher num-
bers at the 72 h time point. This difference was mainly
reflected by initially (HCC condition) lower macrophage
numbers (Figure 1B and 1F, Additional File 1, Figure s4
B) and higher numbers of macrophages at the 72 h time
point (Figure 1D and 1H, Additional File 1, Figure s4).
In male mice total BAL cell numbers where constant
and not affected by the treatment (Figure 1A and 1E;
Additional File 1, Figure s4 A). No sex-specific effect
of treatment was observed for BAL neutrophil numbers
(Figure 1C and 1G, Additional File 1, Figure s4 C),
being considered the most significant read out for
inflammation.
Especially the absence of neutrophils in all HCC groups
(Figure 1C and 1G) was evidencing that there was no
pro-inflammatory condition, in absence of a treatment
related stimulus. Twenty-four hours after particle instilla-
tion (CNP-24 h), a significant influx of neutrophil granu-
locytes into the alveolar lumen was observed, indicating
acute lung inflammation in both, wild-type and mutant
animals (Figure 1C and 1G). However, particle instillation
did not cause significant genotype-related differences in
the magnitude of neutrophil recruitment into alveolar
lumen (Figure 1C and 1G). Seventy-two hours after parti-
cle instillation (CNP-72 h) neutrophil numbers were sig-
nificantly lower in comparison to the time point of acute
lung inflammation (CNP-24 h), indicating similar degree
of resolution of inflammation on a cellular level in both
genotypes and sexes (Figure 1C and 1G).
BAL: Protein and Lactate Dehydrogenase (LDH)
Consistent with the absence of any difference in the cel-
lular component of the inflammation we did not observe
differences in the alveolar-capillary barrier function and
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Figure 1 Bronchoalveolar lavage (BAL) cell differentials. BAL cells of female (A.-D.) and male (E.-H) PPARg wild-type (wt/wt) (white bars) and
PPARg mutant mice (P465L/wt) (grey bars). Untreated home cage controls (HCC); water-instilled animals at 24 h time point (SHAM-24 h);
particle-instilled mice at 24 h (CNP-24 h) and 72 h time point (CNP-72 h). For sample size, please see Table1. Statistics: General Linear Model
(GLM): BAL Cell Number: genotype: F/W = 11.045, df = 1,**P = 0.001; treatment: F/W = 12.254, df = 3, ***P < 0.001; sex: ***P < 0.001; treatment × sex:
F/W = 6.449, df = 3, ***P < 0.001; BAL Macrophages: genotype: F/W = 29.434, df = 1, ***P < 0.001; treatment: F/W = 9.767, df = 3, ***P < 0.001; sex:
F/W = 14.869, df = 1, ***P < 0.001; treatment × sex: F/W = 4.697, df = 3, **P = 0.0039; BAL Neutrophils: genotype: F/W = 7.274, df = 1, **P = 0.008;
treatment: F/W = 103.631, df = 3, ***P < 0.001; sex: F/W = 0.892, df = 1, P = 0.347; BAL Lymphocytes: genotype: F/W = 0.352, df = 1, P = 0.5543;
treatment: F/W = 17.437, df = 3, ***P < 0.001; sex: F/W = 0.059, df = 1, P = 0.810; treatment × sex: F/W = 2.944, *P = 0.036;
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found no indications of increased lung injury in the
mutant mice, as usually indicated by increased BAL pro-
tein. Total BAL protein content did not differ between
PPARg (wt/wt) and PPARg (P465L/wt) mice of both
sexes under untreated HCC, SHAM, and CNP condi-
tions after 24 h and 72 h (Additional File 1, Figure s1 A
and C), respectively. This agreed with the fact that con-
centrations of the intracellular enzyme LDH in BAL
supernatant were not different between HCC groups.
Also no differences were observed in LDH levels 24
hours or 72 hours after particle instillation between gen-
otypes (Additional File 1, Figure s1 B and D). All
together, this shows lack of differences in cell membrane
damage and necrotic cell death in BAL cells between
genotypes.
BAL Inflammatory marker (ELISA)
Given that the cellular extent of inflammation was not
different between genotypes we next searched for mole-
cular differences in BAL inflammatory markers. We
selected four pro-inflammatory proteins known to be
induced by carbon-nanoparticle treatment as shown
before [42,48] or known for their inflammatory/neutro-
phil recruiting properties. To be able to localize the
response of particular cell populations we measured
galectin-3 (GAL3) and osteopontin (SPP1), as predomi-
nantly alveolar macrophage derived cytokines (Figure
2A and 2B). To determine the inflammatory status of
the epithelium in response to CNP instillation we inves-
tigated the BAL concentrations of anti-bacterial lipoca-
lin-2 (LCN2/NAGL) and neutrophil recruiting cytokine
CXCL5 (Figure 3A and 3B). This determination was
performed in female mice only.
Analysis of alveolar macrophage derived Gal3 concen-
trations in BAL fluid of female PPARg (P465L/wt)
mutant mice revealed lower levels in comparison to
PPARg wild-type females (wt/wt) (GLM) under all treat-
ment conditions (Figure 2A). In contrast, the opposite
was observed for SPP1, its concentration being higher for
all treatment conditions in PPARg (P465L/wt) mutant
mice in comparison with wild-type (Figure 2B). Concern-
ing epithelial derived BAL CXCL5 and BAL lipocalin-2
no difference between genotypes was observed under
whatever condition tested (Figure 3A and 3B). Values for
BAL lipocalin-2 were markedly induced by particle treat-
ment in both genotypes as indicated at 24 h time point,
and were declining at 72 h time point.
Haematological Analysis - Systemic Activation of Blood
Leukocytes
Since no differences were found dependent on genotypes,
gender (HCC) and treatments (SHAM; CNP-24 h; CNP-
72 h) as far as BAL cell populations were concerned, we
next set to investigate whether PPARg mutations may
affect the recruitment of immuno-competent leukocytes
into the blood stream. Blood cell analysis did not reveal
any difference at all between wild type (wt/wt) and
PPARg (P465L/wt) in both sexes, neither for total white
blood cells (WBC), nor there was a difference in leuko-
cyte subpopulations; lymphocyte, monocyte and granulo-
cyte numbers (neutrophils, eosinophils, and basophils)
(Additional File 1, Figure s2 and s3).
Discussion
The point mutation P467L in human receptor PPARg
has been shown to be associated with adverse effects for
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Figure 2 Markers for Alveolar Macrophages. BAL cytokine concentrations of galectin-3 (A) and osteopontin (SPP1) (B) in female PPARg wild-
type (wt/wt) (white bars) and PPARg mutant mice (P465L/wt) (grey bars) - markers mainly derived from alveolar macrophages and known to be
associated with carbon-nanoparticle-induced pulmonary inflammation. HCC: untreated home cage controls; SHAM-24 h: water-instilled animals at
24 h time point; CNP-24 h: particle-instilled mice at 24 h time point; CNP-72 h: particle-instilled mice at 72 h time point. For sample size, please
see Table1. Statistics: General Linear Model (GLM): Galectin-3: genotype: F/W = 8.194, df = 1, **P = 0.006; treatment: F/W = 6.095, df = 3,**P =
0.001; SPP1: genotype: F/W = 19.786, df = 1, ***P < 0.001; treatment: F/W = 15.921, df = 3, ***P < 0.001;
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human health and well-being, resulting in lipodystrophy,
severe insulin resistance, fatty liver, hypertension, and
lowered adiponectin levels in circulation [5]. In regard
to this specific human situation, mice carrying a tar-
geted point mutation in the ligand-binding domain of
PPARg (P465L), being the equivalent mutation to
human P467L, were generated as an animal model,
which partially confirmed the effects described in
humans particularly when confronted to extreme meta-
bolic challenges [6,7]. We used sex-, age-, and body
mass-matched PPARg mutant mice (P465L/wt) to inves-
tigate the receptor role in a particle-induced model of
aseptic acute lung inflammation.
Here we show PPARg genotype-related differences in
total BAL cell numbers, with increased macrophages and
reduced neutrophil counts in mutant mice. In addition,
our BAL data may also indicate a pro-inflammatory shift
of the M1/M2 balance of alveolar macrophages, since (i)
generally higher BAL osteopontin values in mutant mice
point towards a more pro-inflammatory, M1 polarized
macrophage condition, and (ii) lower galectin-3 values - a
marker for alternative macrophage activation - in turn
indicate reduced M2 polarization. However although
alternative macrophage activation is regarded as a PPARg
driven process, relevant for the resolution of inflamma-
tion, our data can not support the impact of PPARg sig-
nalling on particle elicited lung inflammation. Our study
in fact rather demonstrates that an insult with carbon-
nanoparticle (CNP) challenge, administered by intratra-
cheal instillation of Printex 90 particles to the lungs of
mutant P465L/wt and wild-type mice (wt/wt) produces a
similar extend of inflammatory cell recruitment during
acute inflammation and resolution. That implies that the
course of inflammation assessed in our lung inflamma-
tion model was not affected at cellular level by the sus-
pected macrophage unbalance in P465L/wt mice.
Though the inflammatory reaction provoked by CNPs
was mild as compared with experimental endotoxin
models for instance, the response to CNP still might have
been robust enough to overwhelm PPARg pathways, and
thus mask P465L/wt impairments. We have chosen an
intratracheally delivered dose of 20 μg CNP, which as
already previously described [41,42], resulted in marked
recruitment of inflammatory cells into the alveolar
lumen, without provoking significant epithelial injury.
Accordingly BAL protein and BAL lactate-dehydrogenase
(LDH) levels, indicators of acute lung injury and cell
necrosis, did not show biologically relevant increases.
The dose of 20 μg carbon particles used here represents
a surface area dose of 54 cm2 per mouse, an area pre-
viously related to the surface burden affected within
months of people living in high polluted areas [41]. The
time points of 24 h acute response phase and 72 h resolu-
tion phase are well suited to investigate the proposed
hypothesis, since our results are in line with an earlier
study using the same challenge design (same stimulus
and dose), showing most of inflammatory neutrophil
clearance in BAL fluid 72 h after challenge [42].
We can speculate that the P465L related disturbance
might be limited to the macrophages, and not directly
involve the epithelia compartment. P465L/wt conditions
seem not effective to exacerbate/prevent the initiation or
resolution of a moderate but robust, aseptic, and neutro-
philic inflammation. Accordingly the epithelial-derived
inflammatory marker proteins CXCL5 and lipocalin-2
did not differ between genotypes at any time point. Blood
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Figure 3 Markers for Epithelial Cells. BAL cytokine concentrations of CXCL5 (A), and lipocalin-2 (B) in female PPARg wild-type (wt/wt) (white
bars) and PPARg mutant mice (P465L/wt) (grey bars) - markers mainly derived from lung epithelium, and known to be associated with carbon-
nanoparticle-induced pulmonary inflammation. HCC: untreated home cage controls; SHAM-24 h: water-instilled animals at 24 h time point; CNP-
24 h: particle-instilled mice at 24 h time point; CNP-72 h: particle-instilled mice at 72 h time point. For sample size, please see Table1. Statistics:
General Linear Model (GLM): CXCL5: genotype: F/W = 0.205, df = 1, **P = 0.6524; treatment: F/W = 5.334, df = 3, **P = 0.003; lipocalin-2:
genotype: F/W = 0.007, df = 1, P < 0.9348; treatment: F/W = 56.810, df = 3, ***P < 0.001;
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leukocyte numbers where also not affected by genotype,
and did not reveal any signs for systemic inflammation
upon CNP treatment. The lack of genotype related blood
cell differences contrasts with the observed P465L related
differences in BAL cell numbers/BAL macrophages and
points towards the predominant importance of PPARg in
the alveolar region, without exhibiting systemic effects.
The absence of genotype-related differences in the cel-
lular CNP-driven acute lung inflammation and its resolu-
tion may also be based on the possibility that P465L
heterozygous mutant mice have been able to activate
their mutant receptor, a possibility that may occur if high
concentrations of the ligands are available. In fact it was
previously shown for the respective human mutation,
that increased ligand-concentrations are able to rescue
the partial receptor deficit [49]. High ligand-concentra-
tions are well conceivable for the lipid rich alveolar lining
fluid presenting the direct environment of alveolar
macrophages. Under this assumption future investigation
would have to use a functional null of PPARg in alveolar
macrophages.
Compensation at the genomic level by an upregulation
of wt-PPARg expression in P465L/wt macrophages is
not likely, since the PPARg expression level in mutant
BAL macrophages is very similar to that of wt mice
(120 ± 10% of wt).
The conserved pattern of co-activator molecules used
for the function of different PPARs would have been
expected to contribute to a more pro-inflammatory con-
dition in the alveolar compartment, but basal BAL levels
of classically pro-inflammatory cytokines such like
TNFa revealed unchanged in wt versus mutant mice
(data not shown). In this context the lack of a pro-
inflammatory status in blood system as well as in the
alveolar compartment shows that the organism in whole
can cope with the challenge even under the mutant
PPARg condition. We regard a lack of an increased pro-
inflammatory situation in mutants to be related to the
lipid-rich environment of the macrophage within the
alveolar lining fluid, which may have compensated for a
loss of receptor functionality [49].
Conclusions
Our data contribute to the understanding of PPARg
receptor relevance in the context of alveolar macrophage
biology during lung inflammation or particular resolu-
tion. In contrast to the by Asada 2004 suggested pro-
resolving activity of PPARg [18] during clearance of
apoptotic neutrophils, no changes were found related to
the function of this specific dominant-negative PPARg
point mutation. In order to further address and clarify
the receptor’s specific role in the AM-mediated resolu-
tion of pulmonary inflammation and its possible as well
as suggested role in the transition towards chronic lung
disease, we emphasize the need for further investigations,
particularly by using macrophage specific PPARg knock-
out models.
Methods
Animal Generation and Genotyping
P465L/wt mutant mice were generated and genotyped as
described earlier in [7,50]. P465L/wt mice where
obtained from the University of Cambridge (UK) on a
mixed C57BL/6-129/SvJ background and backcrossed
for 9 generations to C57BL/6J for isogenicity.
Particle Challenge Design and Group Setup
Animals were either instilled with aqueous suspension
(zeta potential: 33 mV; agglomerate diameter in suspen-
sion: 0.17 μm) of Printex90 carbon-nanoparticles (CNP),
a commercially available pigment black from Degussa
(Frankfurt, Germany), (diameter [nm]: 14; organic con-
tent [%]: 1; surface area [m2/g]: 272); as described earlier
in [42]), or pyrogene-free distilled water (SHAM
exposed) respectively or were left undisturbed and served
as controls (Home Cage Control; HCC). For details on
group setup and sample size, see table 1;
Prior to instillation, mice were anesthetized by intra-
peritoneal injection of a mixture of Medetomidin
(0.5 mg/kg body mass), Midazolam (5.0 mg/kg body
mass) and Fentanyl (0.05 mg/kg body mass). The animals
were then intubated by a nonsurgical technique [51].
Using a cannula inserted 10 mm into the trachea, a sus-
pension containing 20 μg CNPs, respectively, in 50 μl
pyrogene-free distilled water was instilled, followed by
100 μl air; the suspension of poorly soluble CNPs was
sonicated on ice for 1 min prior to instillation, using a
SonoPlus HD70 (Bachofer, Berlin, Germany) at a moder-
ate energy of 20 W. SHAM animals were instilled 50 μl
pyrogene-free distilled water only [41]. After instillation
animals were antagonized by subcutaneous injection of a
mixture of Atipamezol (2.5 mg/kg body mass), Flumaze-
nil (0.5 mg/kg body mass) and Naloxon (1.2 mg/kg body
mass) to guarantee their awakening and well-being.
Animals were treated humanely and with regard for alle-
viation of suffering; experimental protocols were
reviewed and approved by the Bavarian Animal Research
Authority.
Blood, Serum, and Bronchoalveolar Lavage (BAL)
sampling
Twenty-four hours or seventy-two hours after instillation,
mice were anesthetized by intraperitoneal injection of a
mixture of xylazine (4.1 mg/kg body weight) and keta-
mine (188.3 mg/kg body weight) and killed by exsangui-
nation. Therefore blood was drawn from the retroorbital
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plexus by a capillary and collected a.) in EDTA covered
tubes (Sarstedt) for haematological analysis (ADVIA
Hematology Systems (Bayer Diagnostics) and b.) non
EDTA-covered tubes to gain blood serum. Subsequently
BAL was performed by cannulating the trachea and
infusing the lungs 4 times with 1.0 ml PBS without cal-
cium and magnesium, in adaptation as described pre-
viously [41]. The BAL fluids from lavages 1 and 2 and
from lavages 3 and 4 were pooled and centrifuged (425 g,
20 min at room temperature). The cell-free supernatant
from lavages 1 and 2 were used for biochemical measure-
ments such as lactate dehydrogenase (LDH), total pro-
tein, and cytokine concentrations. The cell pellet was
resuspended in 1 ml RPMI 1640 medium (BioChrome,
Berlin, Germany) and supplemented with 10% fetal calf
serum (Seromed, Berlin, Germany); the number of living
cells was determined by the trypan blue exclusion
method. We performed cell differentials on the cytocen-
trifuge preparations (May-Grünwald- Giemsa staining;
2 × 200 cells counted) and the number of polymorpho-
nuclear leukocytes (PMNs) was used as a marker of
inflammation.
BAL: Total Protein Content and Lactate Dehydrogenase
(LDH) Assay
Total BAL protein content was determined spectropho-
tometrically with an ELISA reader (Labsystems iEMS-
Reader MF, Helsinki, Finland) at 620 nm, applying the
Bio-Rad Protein Assay Dye Reagent (no. 500-0006;
BioRad, Munich, Germany), as a potential biological
marker for pulmonary capillary leakage and lung injury
[52]. 5 μl BAL fluid/mouse was used for analysis.
For detection of the cytosolic enzyme lactate dehydro-
genase (LDH) (U/ml), characteristic for membrane dama-
ging effects, the Cytotoxicity Detection Kit (Roche
Diagnostics, Germany) was used according to the manu-
facturer’s instructions. LDH concentration in the BAL
fluid (30 μl) was spectrophotometrically determined with
an ELISA reader (Labsystems iEMS Reader MF, Helsinki,
Finland) at a wavelength of 492 nm.
BAL Cytokine Detection (ELISA)
The characteristic carbon-nanoparticle (CNP) induced
alveolar macrophage inflammatory markers osteopontin
(SPP1) (mouse Osteopontin; R&D Duo Sets; Catalog
Number: DY441) and galectin-3 (mouse Galectin-3;
R&D Duo Sets; Catalog Number: DY1197) [48], as well
as the known lung mainly epithelial derived inflamma-
tory markers LIX (CXCL5) (mouse LIX; R&D Duo Sets;
Catalog Number: DY443), and lipocalin-2 (NGAL),
(mouse Lipocalin-2/NGAL; R&D Duo Sets; Catalog
Number: DY1857) [42,48] were assayed from BAL sam-
ples using the respective ELISA kit. One hundred μl of
appropriate BAL fluid dilutions were used. Dilutions
were: SPP1: 1:100; galectin-3: 1:100; lipocalin-2: 1:400;
LIX: undiluted.
Statistics
We tested the effects of the factors genotype (2 levels:
wild-type (wt/wt) and mutant (P465L/wt), sex (2 levels:
male, female) and treatment (4 levels: untreated home
cage control (HCC), water-instilled SHAM group at 24
hours (SHAM), carbon-nanoparticle exposure at time
point 24 hours (CNP-24 h), carbon-nanoparticle expo-
sure at time point 72 hours (CNP-72 h) on different
response variables by the use of a general linear model
design (GLM).
We included the 2-way interaction terms of the fac-
tors (genotype × treatment, genotype × sex, sex × treat-
ment), in order to test whether the treatment showed
differential effects in relation to the different genotypes
and sexes. If not statistically significant, the interaction
term was reduced and the model was re-calculated. In
none of the models investigated the interaction term
genotype × treatment was significant (P > 0.10).
Response variables, which deviated from the normal dis-
tribution, were log-, or square-root-transformed. Nor-
mality of the model residuals was checked visually by
normal probability plots and with the Shapiro-Wilk test,
and we assured the homogeneity of variances and good-
ness of fit by plotting residuals versus fitted values and
by the Levene test. In case of significant interaction
terms, post-hoc comparisons were conducted with the
Tukey test. All statistical analyses were done using the
software SPSS 14.0 (SPSS Inc., Chicago, IL)
Significant P-values by GLM testing are provided in
the figure legends by asterisks (*P < 0.050; **P < 0.010;
***P < 0.001). All data are expressed as mean ± SEM.
Table 1 Group Setup and treatment
Group Home Cage Control (HCC) H20 - 24 h
(SHAM)
Printex90 - 24 h
(CNP-24 h)
Printex90 - 72 h
(CNP-72 h)
Male PPARg +/+ 7 6 7 6
Male PPARg P465L/wt 9 8 11 10
Female PPARg +/+ 8 6 7 7
Female PPARg P465L/wt 9 9 8 6
Group Setup and treatment of investigated male and female wild-type (wt/wt) and PPARg mutant mice (P465L/wt). Numbers of animals investigated per group
are provided.
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Additional material
Additional file 1: Additional Figures s1-s4 containing data of the
Bronchoalveolar Lavage (BAL) protein and Lactate Dehydrogenase
(LDH) content, blood cell differentials and showing sex-specific
effects of treatment on BAL cell differentials.
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